Salivary Amylase‐Responsive Buccal Tablets Wipe Out Chemotherapy‐Rooted Refractory Oral Mucositis
Source abstract
Abstract
Abstract Oral mucositis (OM) is the most common and refractory complication of cancer chemotherapy and radiotherapy, severely affecting patients’ life quality, lowering treatment tolerance, and discouraging patient compliance. Current OM delivery systems mostly affect the comfort of patient use and lead to poor compliance and unsatisfactory effects. Herein, salivary amylases (SAs)‐responsive buccal tablets consisting of porous manganese‐substituted Prussian blue (PMPB) nanocubes (NCs), anti‐inflammatory apremilast (Apr) and starch controller have been engineered. PMPB NCs with large surface area can serve as carriers to load Apr, and their multienzyme‐mimicking activity enables them to scavenge reactive oxygen species (ROS), which thus synergize with Apr to mitigate inflammation. More significantly, the starch controller can respond to abundant SAs in the oral cavity and realize the cascade, continuous, and complete drug release after enzymatic decomposition, which not only aids with high tissue affinity to prolong the resistance time but also improves the comfort of use. The preclinical study reveals that contributed by the above actions, such buccal tablets mitigate inflammation, promote endothelium proliferation and migration, and accelerate wound healing for repressing chemotherapy‐originated intractable OM with positive oral microenvironment and shorter recovery time, thus holding high potentials in clinical translation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Oral health in cancer treatment · Salivary Gland Disorders and Functions · Head and Neck Cancer Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical Ultrasound and Department of Stomatology Shanghai Tenth People's Hospital Tongji University School of Medicine Tongji University NO. 301 Yan‐chang‐zhong Road Shanghai 200072 China
Department of Pharmacy and Central Laboratory Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital University of Electronic Science and Technology of China No. 32, West Second Section, First Ring Road Chengdu 610072 China
Funding
Fundamental Research Funds for the Central Universities
References (49)
Show source-provided references
1. 10.1111/j.1365-2702.2006.01618.x10.1111/j.1365-2702.2006.01618.x ↗
2. 10.1002/cam4.122110.1002/cam4.1221 ↗
3. 10.1038/s41572-019-0064-510.1038/s41572-019-0064-5 ↗
4. 10.1016/j.phymed.2020.15340210.1016/j.phymed.2020.153402 ↗
5. 10.1016/j.mehy.2012.03.00910.1016/j.mehy.2012.03.009 ↗
6. 10.1634/theoncologist.3-6-44610.1634/theoncologist.3-6-446 ↗
7. 10.1016/j.cden.2007.10.00210.1016/j.cden.2007.10.002 ↗
8. Riley P. · Cochrane Database Syst. Rev. · 2015 · 2015
9. 10.3322/caac.2170410.3322/caac.21704 ↗
10. 10.1056/NEJMoa181659410.1056/NEJMoa1816594 ↗
11. 10.1016/j.mattod.2023.01.00210.1016/j.mattod.2023.01.002 ↗
12. 10.1177/107815521985029810.1177/1078155219850298 ↗
13. R‐Caballeroa A. · Int. J. Infect. Dis. · 2012 · 41 · 225
14. 10.1002/advs.20200401410.1002/advs.202004014 ↗
15. 10.1016/j.smaim.2023.01.00410.1016/j.smaim.2023.01.004 ↗
16. 10.1016/j.jconrel.2012.05.02610.1016/j.jconrel.2012.05.026 ↗
17. 10.1016/j.jconrel.2011.01.02710.1016/j.jconrel.2011.01.027 ↗
18. 10.1038/s41467-021-21989-510.1038/s41467-021-21989-5 ↗
19. 10.1016/j.biomaterials.2014.10.02410.1016/j.biomaterials.2014.10.024 ↗
20. 10.1016/j.cej.2022.13658010.1016/j.cej.2022.136580 ↗
21. 10.2147/OTT.S18591510.2147/OTT.S185915 ↗
22. 10.1016/j.cej.2022.13603010.1016/j.cej.2022.136030 ↗
23. 10.1039/D2QM00960A10.1039/D2QM00960A ↗
24. 10.1002/adfm.20220939910.1002/adfm.202209399 ↗
25. 10.1016/j.bioactmat.2022.06.01810.1016/j.bioactmat.2022.06.018 ↗
26. 10.1021/jacs.5b1207010.1021/jacs.5b12070 ↗
27. 10.1021/jacs.8b0522310.1021/jacs.8b05223 ↗
28. 10.1021/acs.nanolett.8b0472910.1021/acs.nanolett.8b04729 ↗
29. 10.1039/C4NR04249B10.1039/C4NR04249B ↗
30. 10.1039/C7CS00663B10.1039/C7CS00663B ↗
31. 10.1186/s12951-021-00897-210.1186/s12951-021-00897-2 ↗
32. 10.1016/j.nantod.2020.10100910.1016/j.nantod.2020.101009 ↗
33. 10.1002/smll.20210625210.1002/smll.202106252 ↗
34. 10.1016/j.chempr.2019.05.02310.1016/j.chempr.2019.05.023 ↗
35. 10.1038/s41467-020-16544-710.1038/s41467-020-16544-7 ↗
36. 10.1002/advs.20210050510.1002/advs.202100505 ↗
37. 10.1021/acsnano.2c0251810.1021/acsnano.2c02518 ↗
38. 10.1002/adfm.20211214510.1002/adfm.202112145 ↗
39. 10.1016/j.jmst.2021.04.03710.1016/j.jmst.2021.04.037 ↗
40. 10.1016/j.jmst.2023.04.02010.1016/j.jmst.2023.04.020 ↗
41. 10.1016/j.jconrel.2019.11.00610.1016/j.jconrel.2019.11.006 ↗
42. 10.1016/j.bioactmat.2022.05.01710.1016/j.bioactmat.2022.05.017 ↗
43. 10.1016/j.actbio.2022.07.01610.1016/j.actbio.2022.07.016 ↗
44. 10.1002/adma.20210566710.1002/adma.202105667 ↗
45. 10.1016/j.jconrel.2021.07.01710.1016/j.jconrel.2021.07.017 ↗
46. 10.1021/acsnano.9b0281610.1021/acsnano.9b02816 ↗
47. 10.1021/acsami.2c0944310.1021/acsami.2c09443 ↗
48. 10.1016/j.bioactmat.2021.01.03510.1016/j.bioactmat.2021.01.035 ↗
49. 10.1016/j.bioactmat.2020.09.00810.1016/j.bioactmat.2020.09.008 ↗